Pyrophosphoric acid
Identification
- Name
- Pyrophosphoric acid
- Accession Number
- DB04160
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Pyrophosphoric acid (DB04160)
- Weight
- Average: 177.9751
Monoisotopic: 177.943225506 - Chemical Formula
- H4O7P2
- Synonyms
- acide diphosphorique
- Diphosphoric acid
- Diphosphorsäure
- Pyrophosphorsäure
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UFarnesyl diphosphate synthase modulatorEscherichia coli (strain K12) - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAluminium Aluminium can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium acetate Calcium acetate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium chloride Calcium chloride can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium citrate Calcium citrate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium glucoheptonate Calcium glucoheptonate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium lactate Calcium lactate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
Purchasing individual compounds or compound libraries for your research?
Learn More- Product Ingredients
Ingredient UNII CAS InChI Key Sodium pyrophosphate O352864B8Z 7722-88-5 FQENQNTWSFEDLI-UHFFFAOYSA-J - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataPyrophosphate Injection, powder, lyophilized, for solution 27.6 mg/1 Intravenous Anazao Health Corporation 2012-05-23 Not applicable US 
Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Mastikids II Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-14 Not applicable US Mastikis Gold II Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-08-13 Not applicable US Mastikis Qingjie Shine Mastic Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-14 Not applicable US Mastikis Qingxin Care Mastic Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-21 Not applicable US Nlihome Dental Care Sodium pyrophosphate (1 g/200g) + D-alpha-Tocopherol acetate (0.18 g/200g) + Silicic acid (30 g/200g) Paste, dentifrice Oral Kumho Dental Pharm. Co., Ltd. 2016-01-02 2018-10-01 US Onetoothclinic Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste Dental Sungwon Pharmaceutical Co., Ltd. 2019-11-14 2019-12-19 US Onetoothclinic Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste Dental CONE MEDICAL Co., Ltd. 2019-11-14 Not applicable US Phosphotec Sodium pyrophosphate (40 mg/1) + Stannous fluoride (0.4 mg/1) Injection, powder, lyophilized, for solution Intravenous Bracco Diagnostics, Inc 1976-10-20 2007-09-30 US Technescan PYP Sodium pyrophosphate (11.9 mg/10mL) + Stannous chloride dihydrate (3.2 mg/10mL) Injection, powder, lyophilized, for solution Intravenous Curium US LLC 2015-10-14 Not applicable US Vontee Sodium pyrophosphate (1.0 g/100g) + Pyridoxine hydrochloride (0.05 g/100g) + Silicon dioxide (5.0 g/100g) + Sodium fluoride (0.22 g/100g) Tablet Oral VONJIL 2020-10-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Mastikids II Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-14 Not applicable US Mastikis Gold II Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-08-13 Not applicable US Mastikis Qingjie Shine Mastic Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-14 Not applicable US Mastikis Qingxin Care Mastic Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste, dentifrice Dental Mastic Korea.Co.Ltd 2020-09-21 Not applicable US Nlihome Dental Care Sodium pyrophosphate (1 g/200g) + D-alpha-Tocopherol acetate (0.18 g/200g) + Silicic acid (30 g/200g) Paste, dentifrice Oral Kumho Dental Pharm. Co., Ltd. 2016-01-02 2018-10-01 US Onetoothclinic Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste Dental CONE MEDICAL Co., Ltd. 2019-11-14 Not applicable US Onetoothclinic Tooth Sodium pyrophosphate (0.5 g/100g) + Silicon dioxide (14 g/100g) + alpha-Tocopherol acetate (0.1 g/100g) Paste Dental Sungwon Pharmaceutical Co., Ltd. 2019-11-14 2019-12-19 US Pyrophosphate Sodium pyrophosphate (27.6 mg/1) Injection, powder, lyophilized, for solution Intravenous Anazao Health Corporation 2012-05-23 Not applicable US Vontee Sodium pyrophosphate (1.0 g/100g) + Pyridoxine hydrochloride (0.05 g/100g) + Silicon dioxide (5.0 g/100g) + Sodium fluoride (0.22 g/100g) Tablet Oral VONJIL 2020-10-01 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal pyrophosphates. These are inorganic non-metallic compounds containing a pyrophosphate as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal pyrophosphates
- Direct Parent
- Non-metal pyrophosphates
- Alternative Parents
- Inorganic oxides
- Substituents
- Inorganic oxide / Non-metal pyrophosphate
- Molecular Framework
- Not Available
- External Descriptors
- phosphorus oxoacid, acyclic phosphorus acid anhydride (CHEBI:29888)
Chemical Identifiers
- UNII
- 4E862E7GRQ
- CAS number
- 2466-09-3
- InChI Key
- XPPKVPWEQAFLFU-UHFFFAOYSA-N
- InChI
- InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)
- IUPAC Name
- (phosphonooxy)phosphonic acid
- SMILES
- OP(O)(=O)OP(O)(O)=O
References
- Synthesis Reference
Kiyoshi Nakayama, Hiroshi Hagino, "Method for preparing cytidine diphosphate choline." U.S. Patent USRE0288861, issued August 15, 1972.
USRE0288861- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000250
- KEGG Compound
- C00013
- PubChem Compound
- 1023
- PubChem Substance
- 46507760
- ChemSpider
- 996
- BindingDB
- 50147591
- 1546425
- ChEBI
- 29888
- ChEMBL
- CHEMBL1160571
- ZINC
- ZINC000006827695
- PDBe Ligand
- PPV
- Wikipedia
- Pyrophosphoric_acid
- PDB Entries
- 1xsp / 2bcq / 2bcr / 2bcs / 2bcu / 2e90 / 2e9t / 2e9z / 2ec0 / 2o1c … show 108 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Completed Treatment Tooth Bleaching 1 Not Available Recruiting Not Available Amyloid Cardiomyopathy, Transthyretin-Related 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Paste, dentifrice Dental Paste, dentifrice Oral Paste Dental Injection, powder, lyophilized, for solution Intravenous Injection, powder, lyophilized, for solution Intravenous 27.6 mg/1 Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 61 °C PhysProp - Predicted Properties
Property Value Source logP -1.4 ChemAxon pKa (Strongest Acidic) 1.7 ChemAxon Physiological Charge -3 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 124.29 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 25.52 m3·mol-1 ChemAxon Polarizability 10.28 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7458 Blood Brain Barrier + 0.9868 Caco-2 permeable - 0.6915 P-glycoprotein substrate Non-substrate 0.8723 P-glycoprotein inhibitor I Non-inhibitor 0.9435 P-glycoprotein inhibitor II Non-inhibitor 0.9596 Renal organic cation transporter Non-inhibitor 0.9497 CYP450 2C9 substrate Non-substrate 0.8692 CYP450 2D6 substrate Non-substrate 0.8528 CYP450 3A4 substrate Non-substrate 0.7126 CYP450 1A2 substrate Non-inhibitor 0.8947 CYP450 2C9 inhibitor Non-inhibitor 0.8759 CYP450 2D6 inhibitor Non-inhibitor 0.9335 CYP450 2C19 inhibitor Non-inhibitor 0.8574 CYP450 3A4 inhibitor Non-inhibitor 0.9413 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9653 Ames test Non AMES toxic 0.828 Carcinogenicity Carcinogens 0.6317 Biodegradation Ready biodegradable 0.835 Rat acute toxicity 2.9431 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8422 hERG inhibition (predictor II) Non-inhibitor 0.973
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- Actions
- Modulator
- General Function
- Metal ion binding
- Specific Function
- Not Available
- Gene Name
- ispA
- Uniprot ID
- P22939
- Uniprot Name
- Farnesyl diphosphate synthase
- Molecular Weight
- 32159.22 Da
References
- Sun S, McKenna CE: Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opin Ther Pat. 2011 Sep;21(9):1433-51. doi: 10.1517/13543776.2011.593511. Epub 2011 Jun 25. [PubMed:21702715]
Enzymes
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Product of
- General Function
- Nad+ synthase activity
- Specific Function
- Catalyzes a key step in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction.
- Gene Name
- nadE
- Uniprot ID
- P18843
- Uniprot Name
- NH(3)-dependent NAD(+) synthetase
- Molecular Weight
- 30636.56 Da
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates